date,title,source
Oct-17-18,Bristol-Myers Squibb to Showcase Immunoscience Research and Biomarker-Guided Treatment Approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting,Business Wire
Oct-19-18,Bristol-Myers Squibb Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden 10 mut/Mb,Business Wire
Oct-19-18,BMY vs. LLY: Which Stock Should Value Investors Buy Now?,Zacks
Oct-19-18,"Today's Research Reports on Trending Tickers: Merck & Co., and Bristol-Myers Squibb",ACCESSWIRE
